Upgrade to SI Premium - Free Trial

EyePoint Pharmaceuticals (EYPT)

12.47 -0.19 (1.50%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form 144/A EyePoint, Inc. Filed by: Lurker Nancy July 22, 2026 5:05 PM - SEC Filing Form 144/A EyePoint, Inc. Filed by: Lurker Nancy July 22, 2026 1:44 PM - SEC Filing Form 144 EyePoint, Inc. Filed by: Lurker Nancy July 21, 2026 4:44 PM - SEC Filing EyePoint Pharmaceuticals settles False Claims Act case for $4.7M July 17, 2026 4:07 PM - StreetInsider Form 8-K EyePoint, Inc. For: Jul 13 July 17, 2026 4:05 PM - SEC Filing EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 16, 2026 7:00 AM - Globe NewsWire Stifel Starts EyePoint Inc. (EYPT) at Buy July 15, 2026 4:07 PM - StreetInsider Form 4 EyePoint, Inc. For: Jul 10 Filed by: Duker Jay S. July 14, 2026 4:08 PM - SEC Filing EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer July 13, 2026 7:00 AM - Globe NewsWire Cantor Fitzgerald Assumes EyePoint Inc. (EYPT) at Overweight July 8, 2026 6:14 AM - StreetInsider These 5 stocks are added to The Mizuho Top Picks List for July July 3, 2026 4:00 PM - StreetInsider Form 4 EyePoint, Inc. For: Jun 30 Filed by: Ribeiro Ramiro July 2, 2026 4:03 PM - SEC Filing Mizuho Reiterates Outperform Rating on EyePoint Inc. (EYPT) June 23, 2026 6:41 AM - StreetInsider Form 8-K EyePoint, Inc. For: Jun 18 June 22, 2026 7:05 AM - SEC Filing EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) June 16, 2026 7:00 AM - Globe NewsWire Form SCHEDULE 13G EyePoint, Inc. Filed by: Commodore Capital LP June 3, 2026 4:40 PM - SEC Filing Form 4 EyePoint, Inc. For: May 25 Filed by: Elston George May 27, 2026 4:06 PM - SEC Filing EyePoint Announces Participation at Upcoming Investor Conferences May 19, 2026 7:00 AM - Globe NewsWire EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 18, 2026 7:00 AM - Globe NewsWire Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Paradigm Biocapital Advisors LP May 15, 2026 4:33 PM - SEC Filing Form 8-K EyePoint, Inc. For: May 14 May 14, 2026 7:05 AM - SEC Filing EyePoint gets third positive safety review for wet AMD drug trials May 14, 2026 7:01 AM - StreetInsider EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data May 14, 2026 7:01 AM - Globe NewsWire Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P. May 13, 2026 9:05 AM - SEC Filing Form 10-Q EyePoint, Inc. For: Mar 31 May 7, 2026 4:08 PM - SEC Filing EyePoint Inc. (EYPT) PT Lowered to $37 at RBC Capital May 7, 2026 8:23 AM - StreetInsider Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT) May 7, 2026 3:18 AM - StreetInsider Citi Opens 30-Day Upside Catalyst Watch on EyePoint Inc. (EYPT) May 6, 2026 4:08 PM - StreetInsider EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c May 6, 2026 7:06 AM - StreetInsider Form 8-K EyePoint, Inc. For: May 06 May 6, 2026 7:05 AM - SEC Filing EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments May 6, 2026 7:00 AM - Globe NewsWire EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 April 29, 2026 7:00 AM - Globe NewsWire Form DEFA14A EyePoint, Inc. April 27, 2026 4:09 PM - SEC Filing Form DEF 14A EyePoint, Inc. For: Jun 18 April 27, 2026 4:06 PM - SEC Filing Full Article List